The Company is pleased to announce the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company effective from a later date to be announced by the Company.
This follows the announcement on May 10, 2023 of her appointment with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023. Professor Peters brings expertise, experience and a wealth of knowledge that will be invaluable to the Company and its shareholders.
At the conclusion of the Annual General Meeting, the Company is delighted to announce the appointment of Professor Mok Shu Kam, Tony, to its Audit Committee, upon his re-election as a Director by the shareholders. Tony brings a wealth of expertise and invaluable insight to the table and the Company looks forward to working with him in this new capacity.
HutchMed is a rapidly-growing, cutting-edge biopharmaceutical company that is dedicated to developing and commercializing targeted therapies and immunotherapies to treat cancer and immunological diseases.
With a global workforce of over 5,000 professionals and a core team of 1,800 in oncology and immunology, HutchMed has already made significant progress in bringing their own cancer drug candidates to patients worldwide, with three drugs already approved and marketed in China.